1 International Federation of Pharmaceutical Manufacturers & Associations RETHINKING THE WAY WE FIGHT BACTERIA
2 2 RETHINKING THE WAY WE FIGHT BACTERIA Table of contents INTRODUCTION 4 - Why will we always need new antibiotics? WHAT IS RESISTANCE? 9 - What would a post-antibiotic era look like? WHAT CAN WE DO TO PREVENT MISUSE AND MINIMIZE THE GROWTH OF RESISTANCE? WHY IS IT DIFFICULT TO DEVELOP NEW ANTIBIOTICS? INFOGRAPHIC CONCLUSION INFOGRAPHIC 7 RECOMMENDATIONS FOR A NEW ECONOMIC MODEL TO INCENTIVIZE INNOVATION, MEET PRESERVATION GOALS AND ENSURE ACCESS TO ANTIBIOTICS IFPMA MEMBERS ANTIBACTERIAL COMPOUNDS PIPELINE INVENTORY 2015
3 RETHINKING THE WAY WE FIGHT BACTERIA 3 Introduction Antibiotics made modern medicine possible. Before the introduction of antibiotics, such as penicillin in the 1940s, infectious diseases as simple as common skin infections claimed countless victims. In the early 1900s, 90% of children with bacterial meningitis died. Complex medical interventions like organ transplants, hip replacements and even chemotherapy are all made possible or better by the use of antibiotics. But a hallmark of antibiotics is that they lose their effectiveness over time as bacteria naturally evolve and mutate and so become resistant to the medicine s power. The problem of antimicrobial resistance (AMR) is growing 1, and seventy years after their introduction the rise of bacterial resistance to popular and historically effective antibiotics has become a grave threat to global public health. We now face the possibility of a future without effective antibiotics for several types of bacteria that cause life-threatening infections in humans. The problem of AMR extends across the globe. In 2013, the CDC released a report 2 stating that in the United States, at least 2 million people become infected with bacteria that are resistant to antibiotics and at least 23,000 people die each year as a direct result of these infections. In the EU, multidrug-resistant bacteria cause about 400,000 infections a year and at least 25,000 deaths annually, and generate healthcare costs and productivity losses of 1.5 billion 3. But while there are high levels of resistance in developed countries, the most alarming levels of resistance are in developing countries. For example a study found that in 2013 more than 58,000 babies died from antibioticresistant infections in India 4. At the global level, a report published by the United Kingdom AMR Review Team estimated that a continued rise in resistance by 2050 would lead to 10 million people dying every year and a reduction of 2% to 3.5% in Gross Domestic Product (GDP). In 2014, a resolution was adopted at the World Health Organization s World Health Assembly calling for the development of a Global Action Plan to fight against Antimicrobial Resistance. The development of a Global Action Plan has considerably increased the visibility of AMR at international level. At a national level, AMR is also gaining prominence on the policy agenda, with the implementation of national action plans. At the regional level, the development of public private partnerships such as IMI in Europe has helped incentivize innovation. Finally, AMR is high on the agenda of the G7 leaders who have publicly referred to this issue as one of the most important global threats. We believe that a globally coordinated, multi-faceted policy approach is urgently needed to address each of the challenges contributing to resistance. IFPMA and its member companies are committed to continue in the fight against antimicrobial resistance. 1 Streptococcus pneumoniae (S. pneumoniae), another common pathogen, causes bacterial meningitis and bacterial pneumonia, among other conditions. In 1987, only 2 of every 10,000 S. pneumoniae infections 0.02 percent were resistant to penicillin, the antibiotic of choice. By 2004, this figure had risen to 1 in 5 20 percent a 1,000-fold increase (CDC 2005). extendingthecure.org/executive-summary 2 Antibiotic Resistance Threats in the United States, Bacterial Challenge: Time to React, ECDC/EMEA Joint Technical Report. Stockholm, Ramanan Laxminarayan et al, Antibiotic resistance the need for global solutions, The Lancet Infectious Diseases Commission, Volume 13, No. 12, p , December 2013.
4 4 RETHINKING THE WAY WE FIGHT BACTERIA WHY WILL WE ALWAYS NEED NEW ANTIBIOTICS? Antimicrobial resistance is a naturally occurring phenomenon. Bacteria have always possessed the ability to protect themselves from naturally occurring antibiotics by acquiring resistance through the exchange of genetic material with other bacteria. This survival mechanism, which bacteria have developed over billions of years, eventually enables them to develop resistance to most antibiotics. As a result, even our most recently approved and most effective drugs will gradually decline in efficacy, making research and development of new antibiotics a constant need. Two further factors have accelerated the development of this resistance: widespread use of antibiotics, and time-consuming diagnostic tools leading to the inappropriate use of antibiotics. Over the last twenty years the resistance problem has increased as antibiotic-resistant bacteria have become more prevalent and multidrug-resistant strains have emerged in many species that cause disease in humans. Stopping AMR might be biologically impossible, but the healthcare community can refine, develop and adopt practices to slow resistance and ensure that the global stock of antibiotics remains viable for a longer period. AN URGENT NEED There is a dearth of new antibacterial medicines as the growth in antimicrobial resistance has been accompanied by a sharp decline in the development of new antibacterial medicines. Over the past three decades only two new classes of antibacterial medicines have been discovered, compared to 11 in the previous 50 years. It is now widely accepted that the increase in resistance and the decline in the number of new drugs coming to market together pose a major threat to health in all countries. The number of antibiotics becoming obsolete due to resistance significantly exceeds the number of new therapies being approved 5. Concerted action is needed to boost antibiotic development, to face a growing public health threat. AVERAGE NEW ANTIBIOTIC MOLECULES PER YEAR DEVELOPED MADE OBSOLETE +3 molecules per year s 50s 60s 70s 80s 90s 00s 10s Source: Michael S. Kinch, Denton Hoyer, et. al.,yale Center for Molecular Discovery. (through 2013) 5 Michael S. Kinch, Denton Hoyer, et. al.,yale Center for Molecular Discovery.
5 RETHINKING THE WAY WE FIGHT BACTERIA 5 IN 2014, 2 NOVEL ANTIBIOTICS AGAINST TUBERCULOSIS WERE APPROVED AFTER A DISCOVERY VOID OF OVER 3 DECADES. Otsuka s Delamanid is a new medication with a novel mechanism of action indicated to treat adults with pulmonary multidrug-resistant tuberculosis (MDR-TB), a form of tuberculosis resistant to at least isoniazid and rifampicin, the main first-line medicines. In 2014, delamanid was approved in Japan and South Korea and granted conditional marketing authorization in the European Union in combination with other existing anti-tb medications. In November 2014 the WHO issued interim policy guidance on the use of delamanid which paves the way for country adoption and future access in other high-burden countries. Janssen s Bedaquiline is a new medicine for pulmonary multi-drug resistant tuberculosis (MDR-TB) with a novel mechanism of action in over forty years. Bedaquiline, which is administered by directly observed therapy, is indicated as part of combination therapy in adults with pulmonary MDR-TB. To date, Bedaquiline has received accelerated approval in the United States and has been registered in the Russian Federation by JSC Pharmstandard; the company Janssen signed a license agreement with in 2013 for Russia and the Commonwealth of Independent States. Additional approvals were granted in 2014 by high burden countries such as South Korea, South Africa, the Philippines and Peru. Regulatory filings have also been submitted in China, India, Thailand, Vietnam and Colombia. The growth of resistance combined with the high attrition rate of antibiotic drugs in development makes it crucial that enhanced investments be made in research and development to ensure that a sufficient pool of antibiotics is available at any time to treat common and rare infections. The recent discovery of new antibiotics should not disrupt sustained efforts in discovering new antibiotics. The fight against antimicrobial resistance is a long term one as new antibiotics will always be needed.
6 6 RETHINKING THE WAY WE FIGHT BACTERIA What is resistance? The Center for Disease Control and Prevention (CDC) defines resistance as the ability of bacteria or other microbes to resist the effects of an antibiotic. Antibiotic resistance occurs when bacteria change in some way that reduces or eliminates the effectiveness of drugs. The bacteria survive and continue to multiply causing more harm 6. Some bacteria are naturally resistant to certain types of antibiotics. However, bacteria may also become resistant in two ways: 1 By a genetic mutation 2 By acquiring resistance from another bacterium 6 For more information visit
7 RETHINKING THE WAY WE FIGHT BACTERIA 7 1 A genetic mutation MUTATION : THE 3 WAYS RESISTANCE BUILDS A Efflux pump: Bacteria pump out the antibiotics before they can start attacking bacteria. 3 MAIN MECHANISMS OF MUTATION CREATING RESISTANCE ANTIBIOTIC BACTERIA B Target mutation: Bacteria change the shape of its targets so that the antibiotic cannot attack it. A Efflux pump The bacteria pump out the antibiotics C Destruction: Bacteria develop the ability to neutralize the antibiotic before it can do harm for example by changing the shape of the antibiotic. B Target mutation TARGETS The bacteria change the shape of their targets C WHY DO WE SAY THERE ARE GOOD AND BAD BACTERIA? Good bacteria act as protectors of our body as they compete with pathogenic bacteria for space and nutrients. Sometimes, we put the population of beneficial bacteria at risk. For example, when we take antibiotics to treat an infection of harmful bacteria, we also kill helpful bacteria. Destruction ENZYME Bacteria s enzymes destroy antibiotics before they can act Source: Adapted from Reflexions, The university of Liege website that makes science accessible.
8 8 RETHINKING THE WAY WE FIGHT BACTERIA 2 By acquiring resistance from another bacterium WHY DOES TAKING ANTIBIOTICS FAVOR THE BUILDING OF RESISTANCE? Antibiotic use promotes development of antibioticresistant bacteria. Every time a person takes antibiotics, sensitive bacteria are killed, but sometimes one of the bacteria survives because it has the ability to neutralize or escape the effect of the antibiotic; that one resistant bacterium can then multiply and replace all the bacteria that were killed off. Repeated and improper uses of antibiotics are primary causes of the increase in drugresistant bacteria. SELECTION PRESSURE: WHY DOES THE USE OF ANTIBIOTICS FAVOR THE EMERGENCE OF RESISTANCE? 1 2 Good & bad bacteria compete for space and nutrients Bad bacteria causing the disease susceptible to antibiotics Good bacteria Resistant bacteria Antibiotics will kill both good and bad bacteria. The resistant bacteria can more easily reproduce. WHAT IS SELECTION PRESSURE? According to the Food and Drug Administration (FDA), selection pressure is the increased prevalence and dissemination of resistance. It is an outcome of natural selection and should be viewed as an expected phenomenon of the Darwinian biological principle survival of the fittest 7. 3 More resistant bacteria are growing in proportion with the use of antibiotic. Some bacteria can transfer the resistance to others 7 For more information: AntimicrobialResistance/ucm htm
9 RETHINKING THE WAY WE FIGHT BACTERIA 9 WHAT WOULD A POST-ANTIBIOTIC ERA LOOK LIKE? The introduction of antibiotics and immunization has been a key contributor to the reduction of deaths from infectious diseases and helped to make modern medicine possible by allowing the use of chemotherapies for cancer, organ transplantation, etc. Chronic diseases are now the leading causes of death. IMPACT OF THE INTRODUCTION OF ANTIBIOTICS ON PUBLIC HEALTH 8 : The 10 leading causes of death as percentage of all deaths United States, 1900 and Tuberculosis Pneumonia Diarrhoea Heart Disease Liver Disease Injuries Stroke Cancer Bronchitis Diphtheria Heart Disease Cancer Stroke Chronic lung disease Unintentional injuries Pneumonia / influenza Diabetes Suicide Chronic kidney disease Chronic liver disease 0% 10% 20% 30% 40% If antibiotics stopped working, the most common health conditions would become impossible to treat and infections resistant to antibiotics would affect people from all ages. Simple infections could become a deadly threat not only for the most fragile, but also any healthy person. 8 Mitchell L. Cohen, Changing patterns of infectious disease, Nature 406, (17 August 2000) doi: /
10 10 RETHINKING THE WAY WE FIGHT BACTERIA WHAT WILL HAPPEN IF WE DO NOT ADDRESS AMR? EPIDEMIOLOGICAL AND ECONOMIC DATA 9 Initial studies looking at what could potentially be the cost of inaction in both epidemiological and economic terms estimated that a continued rise in resistance by 2050 would lead to 10 million people dying every year and a reduction of 2% to 3.5% in Gross Domestic Product (GDP). It would cost the world up to 100 trillion USD. DEATHS ATTRIBUTABLE TO ANTIMICROBIAL RESISTANCE EVERY YEAR COMPARED TO OTHER MAJOR CAUSES OF DEATH AMR in ,000,000 Tetanus 60,000 Cholera 100,000/ 120,000 Measles 130,000 AMR 700,000 Road traffic accidents 1,200,000 Diarrhoeal disease 1,400,000 Diabetes 1,500,000 Cancer 8,200,000 Source: Adapted from the Review on Antimicrobial Resistance UK Independent Review Team Report, December 2014.
11 RETHINKING THE WAY WE FIGHT BACTERIA 11 EXAMPLES OF HEALTH CONDITIONS AND INTERVENTIONS WHICH WOULD NOT BE POSSIBLE WITHOUT EFFECTIVE ANTIBIOTICS BABIES & CHILDREN Neo-natal care Diarrhoeal disease ADULTS Appendix operations Women delivering by caesarean section Treatment of sexually transmissible diseases Organ transplantation Urinary tract infections Drug-resistant infections already kill hundreds of thousands a year globally, and by 2050 that figure could be more than 10 million. The economic cost will also be significant, with the world economy being hit by up to $100 trillion by 2050 if we do not take action. Jim O Neill, Chairman of the Review on AMR OLDER PEOPLE Cancer treatments Hip replacement
12 12 RETHINKING THE WAY WE FIGHT BACTERIA What can we do to prevent misuse and minimize the growth of resistance? Education Prevention Optimized use
13 CS RETHINKING THE WAY WE FIGHT BACTERIA 13 EDUCATION Antibiotics are a critical element in managing bacterial infections in people of all ages. However, inappropriate use and overuse have the potential to make them ineffective over time and taking antibiotics for the wrong illness can be dangerous. Preventing resistance requires healthcare professionals, industry, policy makers and the public to work together in a joint approach to promote appropriate antibiotic use. Educating healthcare professionals and patients is key to minimizing resistance. Antibiotics must be used correctly for the right conditions and only when necessary. Supporting healthcare professionals to make appropriate prescribing decisions and ensuring patients understand their medicines and how to take them is essential. Infections can be caused by two main kinds of germs, viruses and bacteria. Antibiotics only cure infections caused by bacteria. They have no effect against infections caused by viruses, like the flu or colds. Educational programs supporting healthcare providers on getting patients the right medicine at the right time, which includes prescribing only when necessary, can support this approach. 40% of all Europeans wrongly believe that antibiotics work against colds and flu. Public understanding of what antbiotics do and don t treat is critical. When prescribed antibiotics, ensuring patients know how to take the medicine prescribed and understand the importance of finishing the full course of medication is also an essential element to support this understanding. Understanding that most coughs and colds are caused by viruses, which are not cured by antibiotics, is also a key element in education programmes. Antibiotics. Ask your doctor for advice: other medicines can help relieve your symptoms. EUROPEAN ANTIBIOTIC AWARENESS DAY A EUROPEAN HEALTH INITIATIVE Treat colds and flu with care. Talk to your healthcare provider. As a parent, you want to help your child feel better. But antibiotics aren t always the answer. They don t fight the viruses that cause colds and flu. What will? Fluids and plenty of rest are best. Talk to your healthcare provider. Find out when antibiotics work and when they don t. The best care is the right care. For more information, please call CDC-INFO or visit
14 14 RETHINKING THE WAY WE FIGHT BACTERIA PREVENTION In contrast to the challenge of resistance to antibiotics, vaccines remain a consistent weapon in the fight against infectious diseases. While they are not efficacious in people already infected, vaccines can help directly in the fight to limit resistance to antibiotics because they 1) reduce the need for antibiotic use; 2) have the potential to reduce the misuse of antibiotics (e.g. where the vaccine targets a viral infection); and 3) combat bacteria that are resistant to available antibiotic treatments so as to stop the spread of the disease. In each case, vaccines lower the spread of pathogenic bacteria which in turn allows for better management of antibiotics. Vaccines will continue to be a key weapon in our arsenal to reduce the spread of antibiotic resistance. Examples of the three-fold role of vaccination. 1. Immunization can help reduce the use of antibiotics (for example for tuberculosis or pneumonia); it therefore indirectly reduces the opportunities for resistant bacteria to develop. IMPACT OF THE INTRODUCTION OF PNEUMOCCOCAL VACCINE ON INFECTION CONTROL AND ON RESISTANCE Vaccination helps reduce the volume of antibiotics used by preventing infection. Because the volume of antibiotics used decreased, the emergence of penicillin resistant diseases also decreased. Incidence (cases per 100,000) Penicillin-nonsusceptible disease Vaccine Introduced Penicillin-susceptible disease Source: Adapted from Kyaw M. H., et al Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354:
15 RETHINKING THE WAY WE FIGHT BACTERIA Immunization helps reduce the misuse of antibiotics. In the case of viral vaccines, protection from a virus will reduce the number of viral infections which in some cases are mistakenly diagnosed as a bacterial infection and thus treated with antibiotics. For example there is a common misuse of antibiotics against influenza. Immunization may help prevent the development of resistant bacteria (c. difficile, E, Coli, s. Aureus etc.) A NON-EXHAUSTIVE LIST OF EXISTING VACCINES TARGETING POTENTIALLY ANTIMICROBIAL RESISTANT BACTERIA 10 DISEASES PATHOGEN VACCINE TYPE(S) Cholera V. cholerae Inactivated, recombinant toxin subunit Diphtheria C. diphtheria Toxoid Invasive pneumococcal disease S. pneumoniae Polysaccharide Meningitis N. meningitidis Polysaccharide, conjugate Meningitis, pneumonia, epiglottis H. influenzae type B Conjugate Tetanus C. tetani Toxoid Meningitis, bacteremia/sepsis, (pneumonia), otitis media S. pneumoniae Conjugate Typhoid fever S. typhi Polysaccharide, Live attenuated Whooping cough B. pertussis Inactivated, sub-unit, toxoid Source: Vaccines Europe, Role of vaccination in reducing antimicrobial resistance, June More vaccines targeting bacteria are currently under development as described in the pipeline inventory featured at the end of this publication. 10 Vaccines Europe, Role of vaccination in reducing antimicrobial resistance, June uploads/2013/09/amr-and-vaccines-june-2013.pdf
16 16 RETHINKING THE WAY WE FIGHT BACTERIA OPTIMIZED USE The use of rapid test diagnostics The ability to identify targeted pathogens with rapid diagnostic tests (RDTs) could greatly improve appropriate treatment involving the use of antibiotics. Currently, the most accurate and widespread identification of bacteria takes hours to provide results. As delays in initiation of effective therapy can lead to increased sickness or even death of the patient, physicians frequently must treat patients empirically while still waiting for test results, or may not even undertake those tests at all. This may lead to inappropriate prescription of antibiotics or even the misdiagnosis of viral infections as bacterial. The absence of effective RDTs has also led physicians to rely on broad spectrum antibiotics as opposed to more targeted treatments. We must be realistic about what can be achieved through improved diagnostics: even the latest tools can take 24 hours or more to produce a result, and they often require a level of resources that in developing country settings limit their use. Nevertheless, improved diagnostic tools are an important part of the response to the AMR challenge. Combatting the use of sub-standard and falsified medicines Available data suggest that antibiotics are one of the most falsified and/or substandard pharmaceutical products in developing countries 11. Substandard antibiotics often have a lower dosage of the active ingredient which directly contributes to build resistance 12, as what does not kill bacteria makes them stronger. A study published in the International Journal of Tuberculosis and Lung Disease 13 assessed the quality of two treatment packs of two first-line anti-tuberculosis drugs in 19 cities in 17 low- and middle-income countries. The study showed that 9.1% of the drugs sampled failed basic quality control tests. The failure rate was 16.6% in Africa, 10.1% in India, and 3.9% in other middle-income countries. Approximately half of these failing products contained some active ingredients making them likely to contribute to drug resistance. In addition, falsified medicines may contain the wrong ingredients, the wrong dose, no active ingredients at all or dangerous substances. Ensuring the good quality of antibiotics and securing the supply chain are necessary measures to prevent the development and spreading of multi-resistant bacteria. Stewardship Antibiotic stewardship must be an integral part of any solution to overcome antibiotic resistance. Cases where antibiotics are overused or misused exist worlwide. To address this, clear guidelines and pathways for medical intervention, including timelines, are required to stabilize the growth of resistance antibiotic. Stewardship programs can facilitate the use of appropriate treatment protocols and trigger appropriate reporting processes that will combat the development of bacterial resistance. For any of these programs the challenge will be not to become a gatekeeper to antibiotic usage. Adequate antibiotic stewardship must be a systematic effort from multiple partners. Governments and policymakers can implement systems that reward healthcare providers for implementing high quality stewardship programs. Hospital systems, individual hospitals and medical societies and physicians, as well as IT teams that support efficient information-sharing and analysis can all contribute towards ensuring that all aspects of appropriate use of antibiotics are captured 11 WHO. Counterfeit Drugs: Guidelines for the Development of Measures to Combat Counterfeit Drugs. Geneva: WHO, 1999; Michael A. Kohanski, Mark A. DePristo, James J. Collins. Sublethal Antibiotic Treatment Leads to Multidrug Resistance via Radical-Induced Mutagenesis. Molecular Cell, Volume 37, Issue 3, , 12 February 2010 DOI: /j.molcel Bate R, Jensen P, Hess K, Mooney L, Milligan J (2013) Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis 17: Available:
17 RETHINKING THE WAY WE FIGHT BACTERIA 17 in high quality stewardship programs. Pharmaceutical manufacturers can also partner with health care delivery systems to share information and expertise that will contribute towards the development of robust and responsible stewardship programs. IFPMA s member companies adhere to the conditions of IFPMA Code of Pharmaceutical Marketing Practices 14, supplemented by member association and company Codes, which set standards for the ethical promotion of medicines. IFPMA calls on other stakeholders to adopt codes of practice with regard to the marketing and prescribing of medicines. In addition, the pharmaceutical industry and national industry associations have participated in the development of national action plans and workshops on how to reduce antibiotic use. It is only through ongoing, sustainable partnerships that we can tackle this challenge. EXAMPLE: ANTIBIOTIC STEWARDSHIP PROGRAMMES IN INDIA India suffers from significant rates of resistance to antibiotics and unfortunately, the use of antibiotics is not monitored systematically. Antibiotics can be bought over-the-counter in India and to date, the government has not established clear guidelines for the use of antibiotics. With 20,000 hospitals and over a million people in India, a systemic approach is crucial to any anti-microbial stewardship effort. In 2012, a partnership was initiated across multiple medical societies in India, to establish A Roadmap to Tackle the Challenge of Antimicrobial Resistance. This first step toward systemic change outlined the roles and responsibilities of many groups well positioned to improve the use and monitoring of antibiotics, including the Indian government, semi-governmental agencies, physician associations, hospital administrators, medical educators and medical journals. With such a comprehensive assessment now public, the work of reaching each and every one of the 20,000 hospitals and of changing the mindset that has promoted such free use of antibiotics has begun. Region by region, hospital by hospital, the partnerships between government, the health care providers and also the pharmaceutical industry are starting to make a difference. The impact of these efforts, will overtime significantly help reduce antimicrobial resistance rates across India. 14
18 18 RETHINKING THE WAY WE FIGHT BACTERIA Why is it difficult to develop new antibiotics? A UNIQUE CHALLENGE There is a unique market dynamic for antibiotics where new therapies should be used at a minimum level to ensure their preservation and delay as much as possible the development of resistance. This dynamic goes against the traditional economic market logic, which is based on a price/volume model. To ensure continued investment in antibacterial R&D, a new economic model must be developed.
19 RETHINKING THE WAY WE FIGHT BACTERIA 19 Antibiotics generally provide a low return on investment. This is explained by different factors: The limited use of new therapies because they are kept in reserve as medicines of last resort. The relatively short period for which antibiotics are taken compared with drugs for chronic diseases. DEVELOPMENT Clinical trials on new antibiotics are difficult to carry out. Because placebo-controlled trials for serious bacterial infections are unethical, scientists need to use a more challenging (non-inferiority) design for trials of new antibiotics. Regulators need to find a balance between statistical conservatism and physician and patient needs 16. Antibiotics development costs can be very high where highly selective patient populations are required (patients with resistance to existing treatments) to carry out clinical trials. While effective new antibiotics provide a range of benefits to society, there is still a low value placed on them. This calls for a broader consideration of value than traditional reimbursement approaches 15. There are 3 main types of challenges for manufacturers in the development of new antibiotics: DISCOVERY The discovery of new antibiotics is not a simple task. Scientific challenges are immense in new antibiotics research given the existence of multiple resistance mechanisms. As a result, progress depends on sustained efforts by industry over a period of many years, combined with the existence of, as well as scientific progress by, diverse groups of trained scientists within academia and industry. EXAMPLE: CLINICAL TRIALS FOR NEW TUBERCULOSIS (TB) MEDICINES Clinical trials are often lengthy since standard TB treatment requires several months of daily observed therapy of the study drug combined with a cocktail of existing drugs and for drug-resistant forms of TB, treatment could be up to 24 months. This means in order to effectively produce clinical trial results for regulatory approval, one must complete the full 24 month observation period plus a follow up. When added all together, this means taking studies through phase III requires more than 5 years. Additionally, the several drugs required to compose the regimen must also be procured and paid for by the study sponsor. This long treatment regimen poses a huge cost to ensure patient compliance and proper pharmacovigilance. 15 Kevin Outterson, John H. Powers, Gregory W. Daniel and Mark B. Mc Clellan, Repairing The Broken Market For Antibiotic Innovation, Health Affairs, 34, no.2 (2015): Letter from IDSA to FDA Division of Dockets Management. The Infectious Diseases Society of America s Commentary on Food and Drug Administration Draft Guidance HFA November 2010.
20 20 RETHINKING THE WAY WE FIGHT BACTERIA ECONOMIC The low value placed on antibiotics; effective new antibiotics provide a range of benefits to society, calling for a broader consideration of value than traditional reimbursement approaches. The limited use of new therapies because they are kept in reserve as medicines of last resort. The relatively short period for which antibiotics are taken compared with drugs for chronic diseases. EXAMPLES: THE LOW VALUE PLACED ON INNOVATIVE ANTIBIOTICS For patients with severe Multiple Drug Resistance (MDR) infections, treatment with an innovative antibiotic effective against MDR pathogens can mean the difference between life and death. Budget and payment structures do not always differentiate first line antibiotics with innovative antibiotics effective against MDR pathogens. This negatively impacts health systems ability to reimburse innovative antibiotics. Severe MDR strains of formerly treatable pathogens can emerge rapidly, potentially causing outbreaks of multi-resistant infections that imperil significant populations as well as causing major economic disruption. A diversity of effective antibiotics can provide the necessary protection against such a scenario, but traditional added value analysis places no value on this type of antibiotic diversity. antibiotics 17. Research has shown that the current reimbursement environment sends incorrect signals to antibiotics developers, because the return on new antibiotics that address the significant harms of AMR is far less than the societal value that these drugs deliver 18. To re-incentivize investment in antibiotic R&D, a new economic model is needed that includes both push and pull mechanisms. INCENTIVISING NEW R&D FOR ANTIBIOTICS Push mechanisms move research forward; they help de-risk companies initial investments by pooling funds and expertise. Public Private Partnerships (PPPs) help derisk initial investment by sharing cost and pooling expertise. This cooperative tool is a crucial link in the process of bringing new discoveries to patients, particularly where there is little commercial investment. While PPPs are helping offset some of the R&D costs, they are not a structural solution as they focus on development and supply and do not address the need for sufficient ROIs. Tax credits increase the return on investment of successful medicines by subsidizing the cost of R&D through the reduction of tax liability. While tax credits can help de-risk R&D investments, they usually do not have the ability to incentivize investment in R&D on its own if there is a clear market failure. Also, this push mechanism mostly appeals to bigger companies. As a consequence to these barriers, many companies have scaled down their capabilities for developing new Pull mechanisms encourage funding by helping increase the potential ROI and improving the predictability of the demand. 17 Kinch MS et al. Drug Discovery Today, July Sertkaya, Eyraud, Birkenbach, Franz, Ackerley, Overton, and Outterson, Analytical Framework for Examining the Value of Antibacterial Products US Department of Health and Human Services, April, 2014
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
2013 Indiana Healthcare Provider and Hospital Administrator Multi-Drug Resistant Organism Survey Antibiotic resistance is a global issue that has significant impact in the field of infectious diseases.
DEVELOPING WORLD HEALTH PARTNERSHIPS DIRECTORY OVER 250 HEALTH PARTNERSHIPS THAT MAKE A DIFFERENCE TO PEOPLE S LIVES The global health community needs to overcome both new and current challenges in the
1/5 Draft political declaration of the high-level meeting of the General Assembly on antimicrobial resistance We, Heads of State and Government and representatives of States and Governments, meeting at
3 rd February 2014 THE 3P PROJECT An overview of the 3P proposal to accelerate innovation and access for new treatment regimens for TB WHY THE 3P PROJECT FOR TUBERCULOSIS IS NEEDED Tuberculosis (TB) mainly
Taking a Leap Toward Global Supply Chain Efficiency 2 Taking a Leap Toward Global Supply Chain Efficiency INTRODUCTION PROBLEM STATEMENT Pharmaceutical manufacturers face a number of challenges to produce
PRIORITY RESEARCH TOPICS Understanding all the issues associated with antimicrobial resistance is probably impossible, but it is clear that there are a number of key issues about which we need more information.
Vaccination: It s what your child would choose No-one likes an injection, but your child would never choose to suffer from serious conditions like measles, mumps or whooping cough. Your guide to childhood
healthcare associated infection A C T I O N G U I D E 1.2 AUSTRALIAN SAFETY AND QUALITY GOALS FOR HEALTH CARE What are the goals? The Australian Safety and Quality Goals for Health Care set out some important
The Basics Why should I get vaccinated? Vaccination is the best way to protect against infections that can make you sick and be passed on to those around you. 1 What kinds of side effects will I get from
The Burgeoning Public Health Crisis: Demand Analysis and Market Opportunity for Advanced Trauma Systems in the Developing World Globally, the causes of mortality will experience significant shifts over
COUNCIL OF THE EUROPEAN UNION Brussels, 22 May 2008 9637/08 SAN 88 DENLEG 52 VETER 7 NOTE from: Committee of Permanent Representatives (Part 1) to: Council No. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER
The Onslow County Health Department Travel Clinic offers a complete line of immunizations and prescriptions to protect you while traveling abroad. The most appropriate immunizations and travel medications
Information on Measles and Whooping Cough: Vaccination and Disease Vaccine s Mechanism of Action Vaccines expose the recipient to a small amount of an weakened organism. Through this exposure, the body
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
AMR: from science to patienttranslating research into medical practice Scientific support for public health: existing Actions, New challenges and European added value 14 th November 2013 1 The Objective
C. difficile Infections Introduction C. difficile is a type of bacteria that can cause diarrhea and infection of the colon. This bacterium is more likely to infect patients at hospitals and other healthcare
What is whooping cough Ocument dn (pertussis)? Information and Prevention IMPORTANT Pertussis (or whooping cough) is a highly contagious infection that can cause uncontrollable, violent coughing. If you
FOREWORD We stand at a crossroads as the United Nations move from the 2015 Millennium Development Goals (MDGs) to the Sustainable Development Goals (SDGs) for 2030. Integral to this transition, the world
Borderless Diseases By Sunny Thai Millennium Development Goal #6 6. Combat HIV/AIDS, malaria and other borderless diseases. A. Halt and begin reversing spread of HIV by 2015. B. Achieve universal access
Tuberculosis What is tuberculosis? TB, or tuberculosis, is a disease caused by bacteria caused Mycobacterium tuberculosis. It is spread from person to person through the air. TB usually affects the lungs.
X-Plain Pediatric Tuberculosis Reference Summary Introduction Tuberculosis, or TB, is a bacterial infection that causes more deaths in the world than any other infectious disease. When a child gets TB,
Personalised Healthcare Frequently Asked Questions Foreword In one sense, personalised healthcare is nothing new. It is what doctors have aimed to provide for their patients through the exercise of their
1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms
IMMUNISATIONS You may want to know if your child should have routine immunisations and whether there could be an increased risk of complications because of the heart condition. We have sought the opinions
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
Chapter 40 The Immune System and Disease Section 40 1 Infectious Disease (pages 1029 1033) This section describes the causes of disease and explains how infectious diseases are transmitted Introduction
X-Plain Avian Influenza or Bird Flu Reference Summary Introduction Avian influenza is an infection caused by avian influenza viruses. Avian means bird and flu is an abbreviation of influenza. Avian flu
Contents Babies from Birth to Age 2... 2 Vaccines give parents the power... 2 Vaccines are recommended throughout our lives... 3 Talk to your doctor... 3 Vaccines are very safe... 3 Whooping Cough (Pertussis)...
Immunization Healthcare Branch Meningococcal Vaccination Program Questions and Answers Prepared by Immunization Healthcare Branch (IHB), Defense Health Agency Last Updated: 27 Mar 06 www.vaccines.mil 877-GET-VACC
C hapter 13 WHY DO WE FALL ILL Multiple Choice Questions 1. Which one of the following is not a viral disease? (a) Dengue (b) AIDS (c) Typhoid (d) Influenza 2. Which one of the following is not a bacterial
ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES AIDS Law Unit Legal Assistance Centre July, 2002 INTRODUCTION Although there is currently no cure for HIV/Aids, treatment has, however, been developed
Why you and your Family Should Get the Flu Shot Why Get VaCCinated against influenza? Influenza (flu) is a virus that can lead to serious complications, hospitalization, or even death. Even healthy children
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
Overview of Tuberculosis Epidemiology, Transmission, Clinical Presentation, and Treatment Tuberculosis Airborne disease caused by the bacterium Mycobacterium tuberculosis (M. tb) M. tb complex (MTBC) includes
Narrowing the Gap Clinical Development and Regulatory Pathways for Medical Technologies for Neglected Diseases Tom Bollyky Stanford Law School Drug Development and International Access Conference April
PNEUMOVAX 23 Pneumococcal Vaccine Single Dose Vial/Pre-filled Syringe What is in this leaflet This leaflet answers some common questions about PNEUMOVAX 23. It does not contain all the available information.
Stem Cells and Hope for Patients by Maureen Condic, Ph.D. Most Americans know someone afflicted with an incurable medical condition. The possibility of stem cell cures has given hope to many who face such
THE DANISH CHILDHOOD VACCINATION PROGRAMME 2015 CONTENTS Introduction 2 The Danish childhood vaccination programme 3 Why do we vaccinate children in Denmark? 4 The diseases 5 Diphtheria 5 Tetanus 5 Whooping
ANTIBIOTIC RESISTANCE THREATS in the United States, 2013 TABLE OF CONTENTS Foreword... 5 Executive Summary.... 6 Section 1: The Threat of Antibiotic Resistance... 11 Introduction.... 11 National Summary
Sounds of Pertussis Pertussis, also known as whooping cough, is a poten tially deadly infection that can strike at any age, but is particularly dangerous for babies. The sounds of pertussis are like no
Factsheet September 2012 Pertussis immunisation for pregnant women Introduction The routine childhood immunisation programme has been very effective in reducing the overall numbers of cases of pertussis.
General Information on Tuberculosis ON THE MOVE AGAINST TUBERCULOSIS: Transforming the fi ght towards elimination World TB Day 2011 SAARC Tuberculosis & HIV/AIDS Centre GPO Box No 9517, Kathmandu, Nepal
RESEARCH ARTICLE Page 1 of 5 Hialeah Nursing and Rehabilitation Center Combines Technology and Best Practices to Improve Infection Control Specific to C.diff ABSTRACT RB Health Partners, Inc., June 24,
Name: Date: Period: Making Background: A vaccine against a disease works by generating an immune response in the body against some kind of pathogen a virus, bacterium or some other agent that causes the
You can get more information about TB from the following: Local Public Health Nurse Community Clinic Nurse Communicable Disease Control Nurse Your Family or Community Doctor Your Infection Control Practitioner
Whooping Cough Introduction Whooping cough is a serious bacterial infection of the lungs and breathing tubes. It is also called pertussis. About 16 million cases of whooping cough happen worldwide each
Manifesto by the European Liver Patients Association (ELPA) on policy measures against chronic liver disease 2014 to 2019 Why this manifesto? Every five years European voters get the opportunity to have
B Keeping Healthy minutes marks Page of 36 Q. A child has a sore throat. The mother takes the child to the doctor. The doctor says that the child has a bacterial infection. Explain how the infection makes
BIG DATA SCIENTIFIC AND COMMERCIAL APPLICATIONS (ITNPD4) LECTURE: DATA SCIENCE IN MEDICINE Gabriela Ochoa http://www.cs.stir.ac.uk/~goc/ OVERVIEW Module My Contributions Description: with guest lectures
FREQUENTLY ASKED QUESTIONS ABOUT PERTUSSIS (WHOOPING COUGH) What is pertussis? General Questions About Pertussis Pertussis, or whooping cough, is a contagious illness that is spread when an infected person
SECURING NEW DRUGS FOR FUTURE GENERATIONS: THE PIPELINE OF ANTIBIOTICS THE REVIEW ON ANTIMICROBIAL RESISTANCE CHAIRED BY JIM O NEILL MAY 2015 2 CONTENTS FOREWORD.... 1 EXECUTIVE SUMMARY....2 1. WHICH NEW
The Challenge of Whooping Cough: Canada s Role in the Development of Pertussis Vaccines AUTHORS: Luis Barreto, M.B.B.S., M.D., M.H.Sc. Rob Van Exan, Ph.D. Christopher Rutty, Ph.D. CREATED THROUGH AN EDUCATIONAL
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
Kidney Disease What YOU need to know International Society of Nephrolo Advancing Nephrology around t A briefing on the global impact of kidney disease - from the International Society of Nephrology Awareness
Key Facts about Influenza (Flu) & Flu Vaccine mouths or noses of people who are nearby. Less often, a person might also get flu by touching a surface or object that has flu virus on it and then touching
DON T GET OR GIVE THE FLU THIS YEAR THANK YOU Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2013-2014 Healthcare workers prevent the spread of flu and
Bile Duct Diseases and Problems Introduction A bile duct is a tube that carries bile between the liver and gallbladder and the intestine. Bile is a substance made by the liver that helps with digestion.
Fighting Disease Name Date Class Infectious Disease This section explains what kinds of organisms cause infectious disease and how infectious diseases are spread. Use Target Reading Skills Before you read,
3P TB R&D Proposal Push, Pull, Pool. Dr Grania Brigden TB Symposium, Yerevan 2015. New treatments and approaches to Tuberculosis Tuberculosis Symposium Eastern Europe MSF and Access Central Campaign Asia
Exploring the Role of Vitamins in Achieving a Healthy Heart There are many avenues you can take to keep your heart healthy. The first step you should take is to have a medical professional evaluate the
The flu vaccination Winter 2013/14 Who should have it and why Includes information for pregnant women Introduction This leaflet explains how you can protect yourself against flu this coming winter, and
Preparing for and responding to influenza pandemics: Roles and responsibilities of Roche Revised August 2014 Table of Contents Introduction... 3 Executive summary... 4 Overview... 4 Roche's role... 4 Roche's
Novartis India Limited Sandoz House Shivsagar Estate Dr Annie Besant Road Worli, Mumbai 400 018 India MEDIA RELEASE MEDIA RELEASE MEDIA RELEASE Novartis extends commitment to help achieve final elimination
Clinical research trials and insurance Information for people who are planning to take part in a clinical research trial January 2011 This information is subject to change depending on medical advances
Pneumonia Education and Discharge Instructions Pneumonia Education and Discharge Instructions Definition: Pneumonia is an infection of the lungs. Many different organisms can cause it, including bacteria,
Health, history and hard choices: Funding dilemmas in a fast-changing world Thomson Prentice Global Health Histories Health and Philanthropy: Leveraging change University of Indiana, August 2006 An embarrassment
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,
C-Difficile Infection Control and Prevention Strategies Adrienne Mims, MD MPH VP, Chief Medical Officer Adrienne.Mims@AlliantQuality.org 1/18/2016 1 Disclosure This educational activity does not have commercial
Tuberculosis: FAQs What is TB disease? Tuberculosis (TB) is a disease caused by bacteria (germs) that are spread from person to person through the air. TB usually affects the lungs, but it can also affect
Aon Kenya Insurance Brokers Ltd Aon Hewitt Healthcare Division Sepsis Awareness Month Issue 11 September 2015 In this Issue 2 Getting to understand Sepsis 3 Stages in Sepsis Advancement 4 Diagnosis & Treatment
Reported cases of pertussis (whooping cough) are on the rise in Colorado and El Paso County. As of October 23, more than 1,000 cases of pertussis have been reported across the state. El Paso County cases
Examples from Health Threats and Opportunities the Scientific Challenges of the 21 st Century Professor Dame Sally C Davies, Chief Medical Officer and Chief Scientific Adviser 6 th th February 2013 Annual
Pentavalent Vaccine Guide for Health Workers with Answers to Frequently Asked Questions Ministry of Health and Family Welfare Government of India 2012 Immunization is one of the most well-known and effective
Swine Flu and Common Infections to Prepare For Rochester Recreation Club for the Deaf October 15, 2009 Supporters Deaf Health Community Committee Members Julia Aggas Cathie Armstrong Michael McKee Mistie
POSITION PAPER 05 January 2011 Addressing the challenge of healthcare associated infections (HCAIs) in Europe A Call for Action Page 1 of 8 A holistic approach to combating HCAIs in Europe We must rise
PROPOSAL by Bangladesh, Barbados Bolivia, and Suriname Prize Fund for Development of Low-Cost Rapid Diagnostic Test for Tuberculosis Executive Summary Date: 09.04.15 The governments of Bangladesh, Barbados,
When treating a disease is bad business: orphan and neglected diseases Rocío Acuña Hidalgo Introduction Over the past decades, the development of thousands of new drugs to treat diseases has improved the
Name ofpolicy: Mandatory Tuberculosis (TB) Screening of Students from World Health Organization Designated High TB Prevalence Countries Policy Number: 3364-81-04-030 T()LED() Revision date: I 0/22/13 Approving
EMA/16634/2014 Summary of the risk management plan (RMP) for Sirturo (bedaquiline) This is a summary of the risk management plan (RMP) for Sirturo, which details the measures to be taken in order to ensure